Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection.
Higher concentrations of tumor DNA in blood correlate with stronger cancer detection, especially in early stages when treatment is most effective.
This multicenter diagnostic biomarker cohort study evaluated Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection. The PubMed abstract reports that it also has a practical implication: we show that rising ccfDNA concentration is associated with higher cancer detection sensitivity, even within disease stages and particularly in early-stage disease-stage I sensitivity varied from 0;55 in the lowest ccfDNA concentration tertile to 0;85 in the highest, and stage II from 0;59 to 0;86.
What the study was
- Study design
- Multicenter diagnostic biomarker cohort study
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Proceedings of the National Academy of Sciences of the United States of America
Why it surfaced
Multicenter diagnostic biomarker cohort study with abstract-backed evidence relevant to Early cancer detection (liquid biopsy, ctDNA, cfDNA); the score reflects study maturity, clinical relevance, and population or unmet-need considerations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.